PDF(Pubmed)
Abstract：
Clinical studies after marketing have shown that the use of glucagon-like peptide-1 receptor agonist(GLP-1RA) may lead to acute kidney injury(AKI). However, few epidemiological studies have investigated the risk, clinical features, and outcomes of AKI caused by different GLP-1RA. In this study, Adverse Event Reporting System (FAERS) data were used to compare the association between different GLP-1RA and AKI in the real world.
FAERS data from January 2004 to December 2021 were mined using disproportionality analysis and Bayesian analysis to determine the correlation between different GLP-1RA and AKI, and the onset time, mortality, and hospitalization rate of different GLP-1RA were analyzed.
We identified 2670 cases of AKI events associated with GLP-1RA, of which liraglutide was the most commonly reported (34.98%). The patients with AKI were mainly males (47.94%), and the age group was mainly 45-84 years old (73.15%). obese patients with weight more than 99kg (24.42%) were more likely to have AKI. According to different signal mining methods, reporting odds ratio (ROR) (1.50, 95% confidence interval =1.41-1.60) and Bayesian confidence Propagation neural network (0.57, 95% confidence interval =0.54), liraglutide was more strongly associated with AKI than other GLP-1RA. The median time to onset of AKI was 63 days [quartile range (IQR): 15-458.5 days]. In addition, the hospitalization rate and fatality rate of patients with GLP-1RA-related AKI were 45.28% and 4.23% respectively.
Based on the data in the FAERS database, we analyzed the risk, onset time, and adverse reaction outcomes of GLP-1RA-induced AKI in detail. The results showed that liraglutide had the highest risk of AKI. From the early stage of treatment, we need to monitor patients\' renal function regularly, especially for patients with high kidney risks such as obesity and age.
FAERS data from January 2004 to December 2021 were mined using disproportionality analysis and Bayesian analysis to determine the correlation between different GLP-1RA and AKI, and the onset time, mortality, and hospitalization rate of different GLP-1RA were analyzed.
We identified 2670 cases of AKI events associated with GLP-1RA, of which liraglutide was the most commonly reported (34.98%). The patients with AKI were mainly males (47.94%), and the age group was mainly 45-84 years old (73.15%). obese patients with weight more than 99kg (24.42%) were more likely to have AKI. According to different signal mining methods, reporting odds ratio (ROR) (1.50, 95% confidence interval =1.41-1.60) and Bayesian confidence Propagation neural network (0.57, 95% confidence interval =0.54), liraglutide was more strongly associated with AKI than other GLP-1RA. The median time to onset of AKI was 63 days [quartile range (IQR): 15-458.5 days]. In addition, the hospitalization rate and fatality rate of patients with GLP-1RA-related AKI were 45.28% and 4.23% respectively.
Based on the data in the FAERS database, we analyzed the risk, onset time, and adverse reaction outcomes of GLP-1RA-induced AKI in detail. The results showed that liraglutide had the highest risk of AKI. From the early stage of treatment, we need to monitor patients\' renal function regularly, especially for patients with high kidney risks such as obesity and age.
摘要：
上市后的临床研究表明，使用胰高血糖素样肽-1受体激动剂（GLP-1RA）可能导致急性肾损伤（AKI）。然而,很少有流行病学研究调查这种风险，临床特征,以及不同GLP-1RA引起的AKI结果。在这项研究中,不良事件报告系统(FAERS)数据用于比较真实世界中不同GLP-1RA和AKI之间的关联。
UNASSIGNED：FAERS从2004年1月至2021年12月的数据是使用不成比例分析和贝叶斯分析进行挖掘的，以确定不同GLP-1RA与AKI之间的相关性，和发病时间，死亡率,分析不同GLP-1RA患者的住院率。
未经证实：我们确定了2670例与GLP-1RA相关的AKI事件，其中利拉鲁肽是最常见的报道（34.98％）。AKI患者以男性为主(47.94%),年龄组主要为45-84岁(73.15%)。体重大于99kg(24.42%)的肥胖患者更有可能发生AKI.根据不同的信号挖掘方法,报告优势比（ROR）（1.50，95％置信区间=1.41-1.60）和贝叶斯信心传播神经网络（0.57，95％置信区间=0.54），利拉鲁肽与AKI的相关性强于其他GLP-1RA。AKI发病的中位时间为63天[四分位数范围(IQR):15-458.5天]。此外,GLP-1RA相关AKI患者的住院率和病死率分别为45.28%和4.23%。
UNASSIGNED：根据FAERS数据库中的数据，我们分析了风险，发病时间,以及GLP-1RA诱导的AKI的不良反应转归。结果表明，利拉鲁肽发生AKI的风险最高。从治疗的早期阶段，我们需要定期监测患者的肾功能,特别是对于患有高肾脏风险的患者，如肥胖和年龄。
UNASSIGNED：FAERS从2004年1月至2021年12月的数据是使用不成比例分析和贝叶斯分析进行挖掘的，以确定不同GLP-1RA与AKI之间的相关性，和发病时间，死亡率,分析不同GLP-1RA患者的住院率。
未经证实：我们确定了2670例与GLP-1RA相关的AKI事件，其中利拉鲁肽是最常见的报道（34.98％）。AKI患者以男性为主(47.94%),年龄组主要为45-84岁(73.15%)。体重大于99kg(24.42%)的肥胖患者更有可能发生AKI.根据不同的信号挖掘方法,报告优势比（ROR）（1.50，95％置信区间=1.41-1.60）和贝叶斯信心传播神经网络（0.57，95％置信区间=0.54），利拉鲁肽与AKI的相关性强于其他GLP-1RA。AKI发病的中位时间为63天[四分位数范围(IQR):15-458.5天]。此外,GLP-1RA相关AKI患者的住院率和病死率分别为45.28%和4.23%。
UNASSIGNED：根据FAERS数据库中的数据，我们分析了风险，发病时间,以及GLP-1RA诱导的AKI的不良反应转归。结果表明，利拉鲁肽发生AKI的风险最高。从治疗的早期阶段，我们需要定期监测患者的肾功能,特别是对于患有高肾脏风险的患者，如肥胖和年龄。
